Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 54Squamous Cell Carcinoma of Head and Neck 4Sarcoma 4Neoplasm Metastasis 4Sarcoma, Ewing 3Neoplasms 3Medulloblastoma 3Lymphoma, Non-Hodgkin 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Astrocytoma 3Wilms Tumor 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Recurrence 2Osteosarcoma 2Oligodendroglioma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioblastoma 2Ependymoma 2Colonic Neoplasms 2Xanthogranuloma, Juvenile 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Teratoma 1Recurrent Squamous Cell Lung Carcinoma 1

Interventions

palbociclib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × CCND1 Gene Amplification × palbociclib × Clear all
NCT02785939 2021-05-27

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

SWOG Cancer Research Network

Phase 2/3 Completed
53 enrolled 15 charts

CCND1 Gene Amplification

Data powered by HemOnc (CC BY 4.0) Colophon âš¡